| Status | Study |
| Recruiting |
Study Name: A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) Condition: Leukemia, Myelomonocytic, Chronic Date: 2017-01-24 Interventions: Drug: Cohort 1, Ceplene® and Proleukin® |
| Recruiting |
Study Name: Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia Condition: Leukemia, Myelomonocytic, Chronic Date: 2016-06-15 Interventions: Drug: Tipifarnib Oral tablet Other Names: |
| Recruiting |
Study Name: Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) Condition: Chronic Myelomonocytic Leukemia (CMML) Date: 2015-08-27 Interventions: Drug: lenzilumab Other Names: KB003 Monoclonal Antibody |
| Withdrawn |
Study Name: A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia Condition: Leukemia, Myeloid, Acute Leukemia, Monocytic, Acute Date: 2015-07-06 Interventions: Drug: Volasertib Addition of s |
| Active, not recruiting |
Study Name: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Condition: Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia Date: 2014-01-28 Interventions: Drug: MEK inhibitor MEK162 Giv |
| Completed |
Study Name: Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Condition: Adult Acute Megakaryoblastic Leukemia Adult Acute Monoblastic Leukemia Date: 2013-06-03 Interventions: Drug: Cytarabine Given IV |
| Recruiting |
Study Name: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia Condition: Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Monoblastic Leukemia (M5a) Date: 2013-02-26 Interventions: Drug: mitoxantrone hydrochloride |
| Active, not recruiting |
Study Name: A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib Condition: Myelomonocytic Leukemia Date: 2013-01-24 Interventions: Drug: Ruxolitinib In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to |
| Completed |
Study Name: Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia Condition: Childhood Acute Monoblastic Leukemia (M5a) Childhood Acute Monocytic Leukemia (M5b) Date: 2012-07-13 Interventions: Other: laboratory biomarker analysis Correlative studies |
| Active, not recruiting |
Study Name: Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Condition: Adult Acute Basophilic Leukemia Adult Acute Eosinophilic Leukemia Date: 2012-06-21 Interventions: Drug: Cytarabine Given IV |